BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 31009836)

  • 1. Vielanin P enhances the cytotoxicity of doxorubicin via the inhibition of PI3K/Nrf2-stimulated MRP1 expression in MCF-7 and K562 DOX-resistant cell lines.
    Gao HL; Xia YZ; Zhang YL; Yang L; Kong LY
    Phytomedicine; 2019 May; 58():152885. PubMed ID: 31009836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway.
    Chen JR; Jia XH; Wang H; Yi YJ; Wang JY; Li YJ
    Int J Oncol; 2016 May; 48(5):2063-70. PubMed ID: 26984633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-line.
    Shaik MS; Chatterjee A; Singh M
    J Pharm Pharmacol; 2004 Jul; 56(7):899-907. PubMed ID: 15233869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chaetominine reduces MRP1-mediated drug resistance via inhibiting PI3K/Akt/Nrf2 signaling pathway in K562/Adr human leukemia cells.
    Yao J; Wei X; Lu Y
    Biochem Biophys Res Commun; 2016 May; 473(4):867-873. PubMed ID: 27038543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vielanin K enhances doxorubicin-induced apoptosis via activation of IRE1α- TRAF2 - JNK pathway and increases mitochondrial Ca
    Zhang LN; Xia YZ; Zhang C; Zhang H; Luo JG; Yang L; Kong LY
    Phytomedicine; 2020 Nov; 78():153329. PubMed ID: 32896708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
    Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
    Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silencing of the CrkL gene reverses the doxorubicin resistance of K562/ADR cells through regulating PI3K/Akt/MRP1 signaling.
    Yu J; Chen WX; Xie WJ; Chen RW; Lin DQ; You WW; Ye WL; Zhang HQ; Lin DH; Xu JP
    J Clin Lab Anal; 2021 Aug; 35(8):e23817. PubMed ID: 34114685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells.
    Dönmez Y; Akhmetova L; İşeri ÖD; Kars MD; Gündüz U
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):823-8. PubMed ID: 20563580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of multidrug resistance by icaritin in doxorubicin-resistant human osteosarcoma cells.
    Wang ZD; Wang RZ; Xia YZ; Kong LY; Yang L
    Chin J Nat Med; 2018 Jan; 16(1):20-28. PubMed ID: 29425587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
    Zhang ZL; Jiang QC; Wang SR
    Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rare dimeric guaianes from Xylopia vielana and their multidrug resistance reversal activity.
    Zhang YL; Xu QQ; Zhou XW; Wu L; Wang XB; Yang MH; Luo J; Luo JG; Kong LY
    Phytochemistry; 2019 Feb; 158():26-34. PubMed ID: 30448739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of multidrug resistance by guggulsterone in drug-resistant MCF-7 cell lines.
    Xu HB; Li L; Liu GQ
    Chemotherapy; 2011; 57(1):62-70. PubMed ID: 21282948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.
    Wang H; Jia XH; Chen JR; Yi YJ; Wang JY; Li YJ; Xie SY
    Int J Oncol; 2016 Dec; 49(6):2529-2537. PubMed ID: 27779650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds.
    Kars MD; Iseri OD; Gündüz U; Ural AU; Arpaci F; Molnár J
    Anticancer Res; 2006; 26(6B):4559-68. PubMed ID: 17201178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
    Chen JM; Bai JY; Yang KX
    IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug resistance mediated by ABC transporters in osteosarcoma cell lines: mRNA analysis and functional radiotracer studies.
    Gomes CM; van Paassen H; Romeo S; Welling MM; Feitsma RI; Abrunhosa AJ; Botelho MF; Hogendoorn PC; Pauwels E; Cleton-Jansen AM
    Nucl Med Biol; 2006 Oct; 33(7):831-40. PubMed ID: 17045162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway.
    Wang Z; Yang L; Xia Y; Guo C; Kong L
    Biol Pharm Bull; 2015; 38(2):277-84. PubMed ID: 25747987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NFκBP65 transcription factor modulates resistance to doxorubicin through ABC transporters in breast cancer.
    Velaei K; Samadi N; Soltani S; Barazvan B; Soleimani Rad J
    Breast Cancer; 2017 Jul; 24(4):552-561. PubMed ID: 27878697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The carotenoid fucoxanthin can sensitize multidrug resistant cancer cells to doxorubicin via induction of apoptosis, inhibition of multidrug resistance proteins and metabolic enzymes.
    Eid SY; Althubiti MA; Abdallah ME; Wink M; El-Readi MZ
    Phytomedicine; 2020 Oct; 77():153280. PubMed ID: 32712543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
    Qian J; Xia M; Liu W; Li L; Yang J; Mei Y; Meng Q; Xie Y
    Eur J Pharmacol; 2019 Jun; 852():231-243. PubMed ID: 30959046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.